Band 9: Many people in poor countries die from diseases that are curable because they cannot afford the medication required. Do you believe that drug companies should make their products available at reduced prices in these countries? Give reasons for your answer and include any relevant examples from your own knowledge and experience.

In the modern era, the field of medical science has made significant progress and produced remedies for a wide array of diseases. Sadly, many people in impoverished nations perish from curable illnesses due to their inability to afford the required medication. I firmly believe that pharmaceutical companies should endeavor to make their products accessible at reduced prices in these countries. In the forthcoming essay, I will elucidate the rationale behind this position and propose viable means to actualize this objective.

First and foremost, it is imperative to delve into the justification for making treatments affordable for the less privileged. Medical innovations represent a significant boon to humanity, the culmination of extensive research and scientific endeavor. The primary ethos underlying these pursuits is to alleviate human suffering and eradicate disease. Consequently, it is morally imperative that the benefits of these advancements are extended to all members of society, regardless of their socioeconomic status. Ensuring affordability of these medications will not only save lives on a large scale but also contribute significantly to the betterment of humanity as a whole.

Moreover, it is essential to consider the pragmatic means through which pharmaceutical corporations can make this a sustainable reality without jeopardizing their financial viability. One viable approach is to collaborate with governmental entities, non-governmental organizations, and charitable institutions to subsidize medication costs in impoverished regions. Additionally, the pharmaceutical industry can incorporate a percentage of their profits towards providing medications at reduced prices as part of their corporate social responsibility. Furthermore, they can support or organize initiatives aimed at fundraising for this noble cause.

In conclusion, it is my firm conviction that accessibility to essential medications should not be contingent upon one’s wealth. Pharmaceutical companies can contribute to this endeavor by offering their products at reduced prices for the financially disadvantaged, through strategic partnerships with humanitarian organizations and by dedicating a portion of their profits to this noble cause. This approach aligns with the moral imperative of ensuring equitable access to life-saving medications for all individuals, irrespective of their financial circumstances.